Agios Pharmaceuticals | AGIO - Ebitda


Agios Pharmaceuticals reported $-120.31M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
AbbVie USD 5.37B 1.85B Dec/2025
Agios Pharmaceuticals USD -120.31M 4.82M Dec/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amgen USD 5.14B 775M Dec/2025
Arrowhead Research USD 57.17M 7.03M Dec/2025
Astellas Pharma JPY 98.93B 84.75B Mar/2026
AstraZeneca USD 5.67B 1.29B Mar/2026
Bayer EUR 4.45B 2.49B Mar/2026
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Exelixis USD 258.29M 15.43M Mar/2026
Gilead Sciences USD 3.02B 1.01B Dec/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
Incyte USD 367.97M 46.53M Mar/2026
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
Merck USD 6.3B 2.09B Dec/2025
Moderna USD -790M 582M Dec/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Novartis USD 5.3B 530M Mar/2026
Novartis USD 5.41B 431M Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sarepta Therapeutics USD -252.2M 84.16M Dec/2025
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026